Renewed interest in the use of antibiotics to prevent travellers' diarrhea has occurred with the availability of non-absorbed rifaximin.
The evidences indicates that a subgroup of travellers with diarrhea have progression of their illnesses to postinfectious irritable bowel syndrome.
|Enterotoxemia E. coli vaccines appear to be a promising addition to travel medicine|
|Alimentary Pharmacology & Therapeutics|
Dr DuPont from Texas, USA summarized recently published information and made recommendations on travellers' diarrhea prevention.
The team reviewed PubMed in 2008 identifying 255 articles on the topic of ‘travellers diarrhea' published from the beginning of 2000.
The researchers found that exercising care in food and beverage selection, while of unproven value, is recommended during travel to high-risk areas of Latin America, Southern Asia or Africa.
The team presented an algorithm to identify future travellers, for which chemoprophylaxis is appropriate.
The team noted that the preferred drug for prevention of travellers' diarrhea is rifaximin, with bismuth subsalicylate or a fluoroquinolone also being effective.
Vaccines against the principal cause of travellers' diarrhea, enterotoxemia Escherichia coli, are being developed.
Dr DuPont's team concluded, "Research is needed to determine the relative effectiveness of exercising care on food and beverage selection.
"Further research is also needed on chemoprophylaxis in preventing travellers' diarrhea, and postinfectious irritable bowel syndrome during high-risk travel."
"Enterotoxemia E. coli vaccines appear to be a promising addition to travel medicine."